This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F20.5 (Residual schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, reduced copayment for 5 years after registration) |
| B. Synonyms | Residual schizophrenia, chronic undifferentiated schizophrenia, Restzustand (schizophrenic), schizophrenic residual state |
| C. Adult onset | Possibility of first onset in adulthood: low — residual schizophrenia is a state that appears as a chronic course after acute episodes of schizophrenia, so schizophrenia first develops (mainly in adolescence to early adulthood) and then forms over years to decades. It does not begin as the residual type from the outset, and a history of previous acute episodes is necessarily required. |
| 1. History | Kraepelin's concept of chronic deteriorating dementia praecox → Bleuler's description of 'residual schizophrenia' → ICD-10 F20.5 classification → subtypes abolished in DSM-5, integrated into the negative symptom dimension. |
| 2. Causes | Long-term course of schizophrenia; inadequate treatment (treatment gaps, poor adherence), accumulation of neurobiological damage from repeated relapses, chronic stress, and social deprivation contribute to formation of the residual state. |
| 3. Genetics | Genetic predisposition common to schizophrenia; repeated relapse and progression to the residual type may be associated with high genetic load and negative symptom–related genes (DTNBP1, NRG1). |
| 4. General epidemiology | About 30–50% of schizophrenia shifts to a residual pattern over the long-term course; a substantial proportion of chronic inpatients are of the residual type; with modern early intervention, the rate of progression to the residual type is trending downward. |
| 5. Pathophysiology | Accumulation of prefrontal dopamine hypofunction and GABA interneuron damage; gray matter and synaptic damage from repeated relapses; interaction between chronic drug treatment and social deprivation. |
| 6. Symptoms | Negative symptom–predominant (affective blunting, avolition, social withdrawal, alogia); residual mild positive symptoms (vague delusional thinking, infrequent auditory hallucinations); accumulating cognitive deficits. |
| 7. Signs | Loss of facial expression, poor self-care, communication breakdown, purposeless behavior; high SANS score; underlying cognitive decline (global decline on MCCB); intermittent bizarre behavior or speech observed. |
| 8. Screening | Regular assessment of negative symptoms with SANS and NSA-16; annual cognitive assessment with MCCB; checking for residual positive symptoms (PANSS); regular testing for physical comorbidities (metabolic syndrome). |
| 9. Diagnosis | ICD-10 F20.5: persistence of negative symptoms after a past schizophrenic episode, with loss or minimization of positive symptoms, lasting at least 1 year; differentiation from depression, drug side effects, and physical illness. |
| 10. Treatment | Clozapine is relatively superior for negative symptoms and cognitive function; cognitive remediation, social skills training; behavioral activation; physical health management (metabolic syndrome, cardiovascular risk); ACT team support. |
| 11. Prognosis | Negative symptoms and cognitive deficits have a limited treatment response; functional outcomes are poor; however, in some patients, functioning can be stabilized with a structured supportive environment and rehabilitation. |
| 12. Prevention | Minimizing progression to the residual type through early intensive treatment; maintenance therapy to prevent relapse; programs for maintaining social function; management of long-term adherence to antipsychotic medication. |
| 13. References | Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia. Lancet Psychiatry. 2018 … and 9 other papers |
The history of residual schizophrenia begins with clinical observation of the long-term course of schizophrenia. Emil Kraepelin saw dementia praecox as ultimately progressing to mental deterioration (Verblödung, dementia). He described that cure or full recovery is rare and that most patients are left with chronic functional decline. This concept is the origin of the clinical recognition of the residual state.
In 1911, Eugen Bleuler described the 'residual state (Residualzustand)' in the chronic stage of schizophrenia, in which positive symptoms disappear and negative symptoms (affective blunting, avolition, autistic withdrawal) predominate. Bleuler regarded this state as one of the natural courses of schizophrenia, and observed that even in the era before drug treatment, some patients stabilized in a chronic negative-symptom state. The German word 'Restzustand' (remaining state) denoted chronic deterioration in the era of Kraepelin and Bleuler, and later became established as the English expression 'residual state'.
The residual type was included as an official subtype in DSM-III (1980). The DSM-III residual type criteria were a history of a previous schizophrenic episode, no prominent positive symptoms currently, but persistent functional decline and mild negative symptoms. DSM-IV (1994) maintained the residual type in the same context. ICD-10 (1992) classified residual schizophrenia as F20.5.
In 2013, with the abolition of all schizophrenia subtypes in DSM-5, the residual type was also removed as an official category. DSM-5 included negative symptoms, cognitive function, and social function as separate dimensional assessment measures to replace the clinical characteristics of the residual type. ICD-10 and ICD-11 retain the residual type code, and F20.5 continues to be used in Korean clinical practice.
As 'negative symptoms' and 'cognitive impairment' have been studied as independent symptom dimensions of schizophrenia in modern research, understanding of negative symptoms and functional decline, the core clinical features of the residual type, has deepened. At the same time, with advances in antipsychotic drugs and the spread of early intervention programs, the clinical paradigm is shifting toward preventing progression to a severe residual state.
The cause of residual schizophrenia is a complex process formed over the long-term course of schizophrenia, understood as the cumulative influence of multiple factors rather than a single cause.
Repeated relapse and accumulation of neurobiological damage: The 'neurotoxic hypothesis' model proposes that repeated acute episodes of schizophrenia accumulate neurobiological damage. With each repeated episode, decreased gray matter volume, especially reduced cortical thickness in the prefrontal and temporal lobes, is observed. There is evidence that this accumulated damage leads to chronicity of negative symptoms and cognitive deficits, but distinguishing it from the effects of antipsychotic drugs themselves on gray matter volume is a research task.
Inadequate treatment and long-term poor adherence: Progression to the residual type is faster and more severe in patients who did not receive appropriate first-episode treatment or who have poor adherence to maintenance pharmacotherapy. The treatment gap and prolonged DUP are important possible factors in formation of the residual state.
Social deprivation and long-term hospitalization: 'Institutionalism' observed in past long-term asylums shows that an unstructured environment, social deprivation, and loss of autonomy induce or worsen negative symptom–like states. The shift to the modern community treatment paradigm works to reduce these environmental causes.
Contribution of chronic antipsychotic drugs: There is a hypothesis that long-term high-dose antipsychotic use induces dopamine supersensitivity, which may paradoxically accelerate negative symptoms and cognitive deficits. This point emphasizes the importance of optimizing drug dose in patients with the residual type.
The genetics of residual schizophrenia is understood in the context of the genetic predisposition to schizophrenia in general and genetic factors specific to negative symptoms.
Negative symptom–related genes: There are studies indicating that genetic variants related to prefrontal function, such as DTNBP1 (dysbindin), NRG1 (neuregulin-1), and COMT Val158Met, are associated with negative symptoms and cognitive deficits. The prominent negative symptom burden in the residual type may be associated with these genetic variants, but large subtype-specific studies are lacking.
High genetic load: There are clinical observations that patients who progress to the residual type tend to have a higher genetic loading than the paranoid type. Whether a high polygenic risk score (PRS) is associated with more severe negative symptoms and cognitive deficits and a poorer long-term prognosis is under study.
Serotonin-dopamine system genes: Some studies suggest that serotonin 5-HT2A receptor gene polymorphisms contribute to residual negative symptoms, which may be related to why the 5-HT2A-blocking action of second-generation antipsychotics shows partial effects on negative symptoms.
Residual schizophrenia is a chronic state seen in the long-term course of schizophrenia, and its prevalence varies according to the course pattern of the schizophrenia patient population.
Prevalence: In long-term follow-up studies, about 30–50% of schizophrenia patients show a residual pattern (negative symptom–predominant, minimal positive symptoms) after 10–20 years. As modern early intervention programs spread, the rate of progression to the residual type is trending downward, but a substantial proportion still experience chronic negative symptoms. A substantial proportion of chronic patients in psychiatric inpatient beds have residual schizophrenia.
Course pattern: The residual type is not so much a diagnosis at a specific point in time as a stage in the chronic course of schizophrenia. Some patients shift to the residual state after several acute episodes and relapse becomes infrequent thereafter, while in others the course alternates between the residual state and acute episodes. Continued maintenance of antipsychotic medication prevents reactivation from the residual state.
Relationship between age at onset and duration of course: Progression to the residual type tends to be faster with early onset (hebephrenic type), and slower or less frequent with late onset (paranoid type). The residual type is most often diagnosed 5–20 years after the first onset.
Epidemiology in Korea: Patients with residual schizophrenia account for a substantial proportion at domestic mental health welfare centers and psychiatric rehabilitation facilities, and their community integration and maintenance of function are major tasks of mental health services. In promoting deinstitutionalization of long-term inpatients, building community support systems for residual-type patients is key. Registration under Special Copayment Reduction (V161) provides the benefit of reduced treatment costs.
The core pathophysiology of residual schizophrenia is chronicity of prefrontal hypofunction and neurobiological fixation of negative symptoms.
Chronic prefrontal dopamine hypofunction: In the chronic course of schizophrenia, decreased dopamine D1 receptor activity and reduced dopamine signaling in the prefrontal cortex (PFC) accumulate. This state forms the neurobiological basis of avolition, alogia, and executive dysfunction. D2 blockade by antipsychotics may further suppress mesocortical dopamine signaling and contribute to negative symptoms.
Reduced synaptic plasticity: Decreased BDNF (Brain-Derived Neurotrophic Factor) has been reported in patients with residual schizophrenia, indicating a reduction in trophic factors needed for synaptic maintenance and neuronal survival. Repeated relapse and chronic stress persistently lower BDNF expression, reducing synaptic plasticity and limiting the capacity for functional recovery.
Accumulated GABA interneuron damage: Damage to parvalbumin (PV)-positive GABAergic interneurons in the prefrontal cortex accumulates over the chronic course, fixing gamma oscillation abnormalities and reduced efficiency of cognitive processing. These abnormalities are known not to be sufficiently corrected by current antipsychotic drugs.
Social reward circuit abnormalities: Anhedonia and avolition, core features of negative symptoms, are associated with abnormalities of reward prediction and motivation circuits in the ventral striatum and prefrontal cortex. Chronic social isolation and deprivation form a vicious cycle that further reduces the function of this circuit.
The clinical symptoms of residual schizophrenia are characterized by prominent negative symptoms with positive symptoms lost or minimized.
Negative symptoms — core features: Five main negative symptoms appear persistently in the residual type. ① Affective blunting/flattening: reduced facial expression, decreased emotional expression, monotone voice. ② Avolition: decreased ability to initiate and sustain goal-directed behavior, reduced activity. ③ Anhedonia: decreased ability to experience pleasure, loss of interest in previously enjoyed activities. ④ Alogia: decreased spontaneous speech, brief and monotonous answers, poverty of thought content. ⑤ Asociality: decreased social interaction, decreased interest in interpersonal relationships.
Residual positive symptoms: In a markedly attenuated form compared with the acute phase, vague delusional thinking, infrequent auditory hallucinations, and mild perceptual abnormalities may remain. These appear in a form that is less distressing to the patient or with reduced intensity of conviction, and do not dominate daily functioning.
Cognitive deficits: Marked decline is seen in working memory, processing speed, executive function, verbal learning and memory, and social cognition alike. Cognitive deficits are the most important predictor of functional recovery and the symptom group with the most limited response to treatment.
Decline in self-care: Overall daily functioning declines, including personal hygiene, clothing care, meal preparation, and management of medication intake. These functions can be partially maintained when supported in a structured environment (day hospital, rehabilitation facility).
The clinical signs of residual schizophrenia are characterized by predominant negative symptoms observed on mental status examination, with positive symptoms lost or minimal.
Appearance and behavior: Poor self-care or need for continuous support. Facial expression is reduced or nearly absent, and eye contact is decreased. Spontaneous movement is decreased, and a passive, withdrawn posture is observed. Purposeless repetitive behavior or bizarre gestures may appear intermittently.
Speech and thought: Spontaneous speech is markedly decreased, and questions are answered with a minimum of words. Thought content is impoverished, so the patient appears to have no interests or plans. The interviewer must lead the conversation, and the patient passively gives only brief responses. Mild delusional thinking may remain vaguely, without logical conviction.
SANS assessment: The Scale for the Assessment of Negative Symptoms (SANS), Brief Negative Symptom Scale (BNSS), or NSA-16 (Negative Symptom Assessment-16) is used to quantify negative symptoms. The SANS total score and the profile of its 5 subdomains (affective blunting, alogia, avolition-apathy, anhedonia-asociality, attentional impairment) are used in diagnosis and assessment of treatment response.
Physical signs — metabolic complications: Signs of metabolic syndrome such as abdominal obesity, hyperglycemia, dyslipidemia, and hypertension are commonly observed due to long-term antipsychotic use, reduced activity, and poor diet management. Regular physical examination and monitoring of metabolic parameters are essential.
In the management of patients with residual schizophrenia, systematic monitoring of negative symptoms, cognitive function, and physical health is key.
Regular assessment of negative symptoms: Regular assessment of negative symptoms using the SANS or BNSS (at intervals of at least 3–6 months) is recommended. Changes in negative symptoms serve as an indicator of treatment response and as a standard for evaluating rehabilitation effect. Depressive symptoms (CDSS) and akathisia (BARS) are assessed at the same time to differentiate secondary negative symptoms.
Annual cognitive assessment: Annual cognitive assessment using the MCCB (MATRICS Consensus Cognitive Battery) is recommended. Cognitive function is important for predicting the potential for vocational rehabilitation and independent living, and is used to set goals for cognitive remediation programs.
Regular physical health examination: Measure blood glucose, lipid profile, blood pressure, weight, and waist circumference at least once a year. In schizophrenia patients, who have a high smoking rate, also assess the risk of smoking-related cardiovascular and pulmonary disease. Regular reassessment to optimize antipsychotic dose is also included.
Checking for residual positive symptoms: Regularly assess residual positive symptoms with the PANSS positive subscale to catch early signs of reactivation. If residual positive symptoms increase, evaluate reactivation factors such as stress, substance use, and decreased medication adherence.
Diagnosis of residual schizophrenia is the process of confirming a chronic negative-symptom state following a past schizophrenic episode and excluding various differential diagnoses.
ICD-10 F20.5 diagnostic criteria: ① There must have been a past episode meeting the criteria for ICD-10 schizophrenia (F20.0–F20.4 or F20.6–F20.9). ② Currently, prominent positive symptoms (delusions, hallucinations, thought disorder) are absent or minimal. ③ Two or more of the following negative symptoms persist for 1 year or longer: psychomotor slowing, decreased activity, affective blunting, poverty of speech, decreased nonverbal communication, decreased self-care, decreased social performance. ④ These symptoms are not explained solely by a depressive episode, physical illness, institutional environment, or antipsychotic drug side effects.
Differential diagnosis: ① Depression (secondary negative symptoms): assess depressive symptoms with the CDSS; if subjective sadness, guilt, or suicidal ideation is present, depression may be more prominent than negative symptoms. ② Antipsychotic-induced symptoms: akinesia due to sedation, EPS, or akathisia resembles negative symptoms; if recovery occurs with dose reduction or change, the cause is secondary. ③ Simple schizophrenia (F20.6): a case that progressed gradually with negative symptoms only, without a clear past acute episode. ④ Organic causes: exclude states resembling avolition/negative symptoms due to neurodegenerative diseases such as Huntington disease, frontotemporal dementia, and Parkinson disease by brain MRI and neuropsychological testing.
The key to treatment of residual schizophrenia is an integrated approach of antipsychotic optimization, non-pharmacologic treatment to improve negative symptoms and cognitive function, and physical health management.
Antipsychotic optimization: With residual positive symptoms minimized, adjust the antipsychotic dose to the minimum effective dose. Because excessive antipsychotic doses can cause secondary negative symptoms, consider careful dose reduction. Clozapine shows relatively the best effect on negative symptoms and cognitive function and is an option for treatment-resistant residual schizophrenia. Aripiprazole, a D2 partial agonist, has the effect of improving secondary negative symptoms (due to excessive drug blockade).
Cognitive remediation: CRT (Cognitive Remediation Therapy), CET (Cognitive Enhancement Therapy), and computer-based cognitive training are used to improve cognitive deficits accompanied by negative symptoms. Social cognition training (SCIT, Social Cognition and Interaction Training) plays an adjunctive role in restoring social function. Cognitive remediation is most effective when combined with functional rehabilitation programs.
Social skills training and rehabilitation: Daily living skills training, prevocational training, and supported employment are key to functional recovery. Structured activity programs at day hospitals and psychiatric rehabilitation facilities are essential for preventing avolition and social withdrawal. Behavioral Activation techniques promote increased activity and positive reinforcement.
Physical health management: Includes monitoring and treatment of metabolic syndrome, smoking cessation support, and regular physical exercise programs. Evidence is increasing that regular exercise (especially aerobic exercise) has a positive effect on negative symptoms and cognitive function.
The prognosis of residual schizophrenia is generally poor, but functional stabilization is possible with a structured supportive environment and active rehabilitation.
Treatment response of negative symptoms and cognitive deficits: With currently available antipsychotic drugs, the effect on negative symptoms and cognitive deficits is limited. Clozapine shows the broadest effect, but complete remission of negative symptoms is rare. The adjunctive effects of non-pharmacologic treatments (cognitive remediation, social skills training, exercise) are increasing, but the effect sizes are moderate.
Functional outcomes: Maintaining independent living is often difficult, and continuous support and assistance are needed. Maintaining employment is often possible only in structured settings such as supported employment. Functional stabilization and improved quality of life are possible in patients with a good family support environment and active participation in rehabilitation.
Risk of reactivation: Even in the residual state, acute positive symptoms can be reactivated by triggers such as stress, medication discontinuation, and substance use. Maintenance antipsychotic medication (LAI recommended) is the key strategy to prevent reactivation.
Physical health and lifespan: Patients with residual schizophrenia have a high risk of metabolic syndrome, cardiovascular disease, and diabetes due to decreased self-care, metabolic side effects of psychiatric medication, smoking, and lack of exercise. Active physical health management is the key to preventing shortened lifespan.
Preventing progression to residual schizophrenia is the most important long-term goal in the management of schizophrenia.
Minimizing progression to the residual type through early intensive treatment: Shortening DUP in first-episode psychosis and achieving full remission with adequate acute-phase treatment is the most effective way to reduce progression to the residual type. Evidence is accumulating that first-episode early intervention programs (EIP) improve long-term outcomes.
Maintenance therapy to prevent relapse: Because repeated relapse accelerates progression to the residual type, maintenance antipsychotic therapy is essential. LAI (long-acting injectables) is one of the most effective ways to improve adherence and prevent relapse.
Programs for maintaining social function: Early rehabilitation of social function such as school, work, and interpersonal relationships can slow progression to the residual type. It is important to start structured programs such as day hospitals, supported employment, and educational support early.
Physical health and lifestyle management: Regular physical exercise, a healthy diet, smoking cessation, and moderation of alcohol contribute to maintaining brain health and slowing cognitive decline. Apply strategies to prevent metabolic complications early in patients on long-term antipsychotic medication.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. DOI: 10.1016/S2215-0366(18)30050-4. PMID: 29909215.
Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia. Neurosci Biobehav Rev. 2011;35(3):573-588. DOI: 10.1016/j.neubiorev.2010.07.001. PMID: 20620163.
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472-485. DOI: 10.1176/appi.ajp.2010.10060855. PMID: 21406461.
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. DOI: 10.1002/wps.20516. PMID: 29745131.
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.
Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14-24. DOI: 10.1002/wps.20385. PMID: 28127915.
Park SC, Jang EY, Park YC. Prevalence, correlates, and impact of schizophrenia on daily life in Korea. Psychiatry Investig. 2018;15(6):580-586. DOI: 10.30773/pi.2017.11.16. PMID: 29961308.